Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis
Frontiers in Oncology · 11.05.2026 · 16
DOI: 10.3389/fonc.2026.1807817 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 11.05.2026. Verfasst von Syed N Rahman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yale University School of Medicine, New Haven, CT, United States. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The diagnosis of variant bladder cancer (VBC) has significant clinical implications, yet remains a challenge for pathologists and clinicians. Our objective was to characterize the changes in VBC diagnosis over time using a national retrospective cohort.
Methods
The National Cancer Database was queried for all cases of pure urothelial and VBC using International Classification of Disease-O-3 morphologic codes from 2004 to 2021. The diagnosis of each type of VBC was trended from 2004 to 2021 to identify significant differences. This was performed in total and across varying facility types (community cancer program, academic program, comprehensive cancer program, and integrated network) with multivariable regression demonstrating significant associations with VBC diagnosis.
Results
Between 2004 and 2021, 753,880 patients with pure urothelial carcinoma (UC) and 30,884 patients with VBC were identified. The diagnosis of VBC across all bladder cancer cases increased from 3.5% of cases in 2004–2009 (first tertile) to 4.3% of cases in 2016–2021 (third tertile) ( p < 0.001), a relative 22.5% rise. This was concentrated in micropapillary subtype, sarcomatoid subtype, and neuroendocrine carcinoma ( p < 0.001). Squamous differentiation did not demonstrate a significant change in diagnosis across time ( p = 0.20). The increase in VBC diagnosis was noted across all facility types, including both community cancer facilities (3.0% of cases in 2004–2009 to 3.7% of cases in 2016–2021) and academic research facilities (4.4% of cases in 2004–2009 to 7.4% of cases in 2016–2021). Multivariable regression demonstrated a significant association between later year of diagnosis, black race, higher clinical stage, and facility type with diagnosis of VBC ( p < 0.05).
Conclusion
Our findings suggest that the diagnosis of VBC is increasing nationally over time. The increase in diagnosis is among micropapillary, sarcomatoid, and neuroendocrine subtypes, and is occurring across comprehensive cancer and academic centers, reflecting the growing need for a centralized review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Yale University School of Medicine, New Haven, CT, United States.
- Division of Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT, United States.
- Department of Pathology, Yale University School of Medicine, New Haven, CT, United States.
Zitieren
APA
Rahman, S. N., Keervani, K., Zhao, X., Perry, C. J., Mu, P., Martin, D., Tan, W. S., Hesse, D. G., Petrylak, D. P., Warrick, J., Kumar, D., Humphrey, P. A., & Ghali, F. (2026). Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1807817
Vancouver
Rahman SN, Keervani K, Zhao X, Perry CJ, Mu P, Martin D, et al. Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1807817
BibTeX
@article{Rahman2026,
author = {Rahman, Syed N and Keervani, Kandala and Zhao, Xiwen and Perry, Curtis J and Mu, Ping and Martin, Darryl and Tan, Wei Shen and Hesse, David G and Petrylak, Daniel P and Warrick, Joshua and Kumar, Deepika and Humphrey, Peter A and Ghali, Fady},
title = {Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1807817}
}
EUVIMED